Concord Biotech Limited (NSE:CONCORDBIO)
India · Delayed Price · Currency is INR 1,238.50
+72.30 (6.20%)
Jun 3, 2026, 12:41 PM IST
Concord Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 2,609 | 3,716 | 3,081 | 2,401 | 1,749 |
Depreciation & Amortization | 744.59 | 543.61 | 535.43 | 538.94 | 498.96 |
Other Amortization | - | 0.13 | 0.49 | 1.39 | 1.55 |
Loss (Gain) From Sale of Assets | -0.13 | 2.25 | -0.12 | 0.94 | 0.34 |
Loss (Gain) From Sale of Investments | -211.28 | -222.64 | -140.65 | -37.17 | -52.3 |
Loss (Gain) on Equity Investments | -29.09 | 13.22 | -33.71 | -19.59 | 36.38 |
Provision & Write-off of Bad Debts | 27.58 | 17.84 | 6.69 | 0.92 | -3.46 |
Other Operating Activities | -332.69 | 81.91 | 17.31 | 96.59 | 71.19 |
Change in Accounts Receivable | 704.53 | -1,708 | -786.6 | -430.97 | -527.69 |
Change in Inventory | -866.89 | -317.13 | 43.61 | -172.27 | -415.12 |
Change in Accounts Payable | -85.2 | 220.89 | -112.87 | 98.81 | 365.35 |
Change in Other Net Operating Assets | 108.33 | 96.54 | 44.06 | -18.42 | 356.91 |
Operating Cash Flow | 2,669 | 2,445 | 2,655 | 2,460 | 2,081 |
Operating Cash Flow Growth | 9.15% | -7.89% | 7.91% | 18.19% | 24.77% |
Capital Expenditures | -951.51 | -1,112 | -856.89 | -1,451 | -1,555 |
Sale of Property, Plant & Equipment | 1 | 1.99 | 1.75 | 0.25 | 0.56 |
Investment in Securities | -500.71 | -598.08 | -718.69 | -184.76 | 395.22 |
Other Investing Activities | 23.98 | 107.95 | 27.73 | 55.85 | 41.4 |
Investing Cash Flow | -1,427 | -1,600 | -1,546 | -1,580 | -1,118 |
Short-Term Debt Repaid | -3.81 | - | - | -43.37 | - |
Long-Term Debt Repaid | -2.73 | -67.45 | -265.04 | -265.96 | -266.56 |
Total Debt Repaid | -6.54 | -67.45 | -265.04 | -309.33 | -266.56 |
Net Debt Issued (Repaid) | -6.54 | -67.45 | -265.04 | -309.33 | -266.56 |
Common Dividends Paid | -1,119 | -915.39 | -714.53 | -535.64 | -705.21 |
Other Financing Activities | -2.83 | -4.84 | -12.58 | -7.23 | -22.26 |
Financing Cash Flow | -1,129 | -987.68 | -992.15 | -852.19 | -994.02 |
Miscellaneous Cash Flow Adjustments | - | - | -0 | - | -14.29 |
Net Cash Flow | 112.82 | -142.38 | 116.43 | 28.32 | -44.77 |
Free Cash Flow | 1,717 | 1,333 | 1,798 | 1,009 | 526.36 |
Free Cash Flow Growth | 28.79% | -25.83% | 78.14% | 91.72% | - |
Free Cash Flow Margin | 16.28% | 11.11% | 17.68% | 11.83% | 7.38% |
Free Cash Flow Per Share | 16.31 | 12.75 | 17.18 | 9.65 | 5.03 |
Cash Interest Paid | 2.83 | 6.33 | 26.5 | 39.58 | 53.15 |
Cash Income Tax Paid | 1,004 | 1,094 | 1,033 | 702.77 | 607.85 |
Levered Free Cash Flow | 1,140 | 926.14 | 1,177 | 505.95 | 188.91 |
Unlevered Free Cash Flow | 1,142 | 929.45 | 1,193 | 534.14 | 223.18 |
Change in Working Capital | -139.23 | -1,708 | -811.8 | -522.86 | -220.55 |